These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8285613)

  • 1. Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum.
    Bernard EM; Edwards FF; Kiehn TE; Brown ST; Armstrong D
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2323-6. PubMed ID: 8285613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.
    Brown BA; Wallace RJ; Onyi GO
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1987-90. PubMed ID: 1416891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
    Perronne C; Gikas A; Truffot-Pernot C; Grosset J; Vilde JL; Pocidalo JJ
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1356-9. PubMed ID: 1656860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
    Gorzynski EA; Gutman SI; Allen W
    Antimicrob Agents Chemother; 1989 Apr; 33(4):591-2. PubMed ID: 2524998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic susceptibility pattern of Mycobacterium marinum.
    Aubry A; Jarlier V; Escolano S; Truffot-Pernot C; Cambau E
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3133-6. PubMed ID: 11036036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
    Barrett MS; Jones RN; Erwin ME; Koontz FP
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium haemophilum: an emerging pathogen.
    Kiehn TE; White M
    Eur J Clin Microbiol Infect Dis; 1994 Nov; 13(11):925-31. PubMed ID: 7698118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1991). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Oct; 48(10):1394-421. PubMed ID: 8544337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.
    Khardori N; Nguyen H; Rosenbaum B; Rolston K; Bodey GP
    Antimicrob Agents Chemother; 1994 Jan; 38(1):134-7. PubMed ID: 8141567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of clinical isolates of Brucella.
    Mortensen JE; Moore DG; Clarridge JE; Young EJ
    Diagn Microbiol Infect Dis; 1986 Jul; 5(2):163-9. PubMed ID: 3720265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.
    Brown BA; Wallace RJ; Onyi GO; De Rosas V; Wallace RJ
    Antimicrob Agents Chemother; 1992 Jan; 36(1):180-4. PubMed ID: 1317144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.